Results 131 to 140 of about 4,926,176 (337)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

The Burden of Prior Authorizations for Pediatric Pulmonary Hypertension Medications: A Quantitative Assessment

Pulmonary Circulation
This study quantified prior authorization (PA)—insurance‐required approval—burden for pediatric pulmonary hypertension (PH) at an accredited center. Among 53 patients, 72% of 283 prescriptions between 2021 and 2023 required PA, with non‐FDA‐approved ...
Delphine Yung, Anne Davis, Kelly Merrill
doaj   +1 more source

Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans. [PDF]

EBioMedicine, 2023
Park M, Kim D, Kim I, Im SH, Kim S.
europepmc   +1 more source

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021 [PDF]

, 2022
David J. Benjamin, Alexander Xu, Mark P. Lythgoe, Vinay Prasad   +3 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness. [PDF]

Int J Environ Res Public Health, 2023
Abdin AY, De Pretis F, Landes J.
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Dostarlimab: From preclinical investigation to drug approval and future directions. [PDF]

Hum Vaccin Immunother, 2023
Cicala CM, Musacchio L, Scambia G, Lorusso D.   +3 more
europepmc   +1 more source

Drug approvals [PDF]

Nature, 1992
openaire   +1 more source

Standards for Approval of DUI Alcohol/Other Drug Information and DUI Alcohol/Other Drug Rehabilitation Programs

, 2013
Oregon Department of Human Services; Addiction Services
openalex   +1 more source